Cramer Rosenthal McGlynn’s Humana HUM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-11,574
Closed -$5.3M 107
2023
Q4
$5.3M Sell
11,574
-14,151
-55% -$6.97M 0.29% 84
2023
Q3
$12.5M Sell
25,725
-1,697
-6% -$797K 0.7% 54
2023
Q2
$12.3M Sell
27,422
-1,127
-4% -$567K 0.61% 61
2023
Q1
$13.9M Buy
28,549
+1,434
+5% +$709K 0.62% 64
2022
Q4
$13.9M Buy
27,115
+1,104
+4% +$580K 0.61% 69
2022
Q3
$12.6M Buy
26,011
+4,698
+22% +$2.29M 0.61% 63
2022
Q2
$9.98M Buy
21,313
+15,438
+263% +$6.87M 0.46% 78
2022
Q1
$2.56M Buy
+5,875
New +$2.46M 0.1% 91
2020
Q3
Sell
-13,905
Closed -$5.39M 98
2020
Q2
$5.39M Sell
13,905
-8,767
-39% -$3.28M 0.22% 84
2020
Q1
$7.12M Sell
22,672
-82,043
-78% -$27.7M 0.34% 80
2019
Q4
$38.4M Buy
104,715
+60,493
+137% +$19.2M 1.09% 29
2019
Q3
$11.3M Buy
44,222
+4,319
+11% +$1.21M 0.32% 98
2019
Q2
$10.6M Sell
39,903
-35,337
-47% -$8.96M 0.29% 96
2019
Q1
$20M Buy
75,240
+16,008
+27% +$4.61M 0.48% 78
2018
Q4
$17M Sell
59,232
-11,883
-17% -$3.77M 0.43% 86
2018
Q3
$24.1M Sell
71,115
-214,603
-75% -$69.7M 0.46% 81
2018
Q2
$85M Buy
285,718
+62,689
+28% +$18.4M 1.53% 13
2018
Q1
$60M Buy
+223,029
New +$60.4M 0.98% 39

Other funds holding HUM

Cramer Rosenthal McGlynn's HUM Position: Q1 2024 in Review

Cramer Rosenthal McGlynn sold out of Humana (HUM) in Q1 2024, closing a stake of 11,574 shares — an estimated $5.3M sold.

Cramer Rosenthal McGlynn first reported a position in HUM in Q1 2018 and held it in 18 quarters. The position peaked at $85M in Q2 2018. 1,029 funds tracked by Wall St. Rank hold HUM as of Q1 2024.

  • Cramer Rosenthal McGlynn reported no remaining Humana position as of Q1 2024 after selling out during the quarter.
  • Cramer Rosenthal McGlynn sold 11,574 Humana shares in Q1 2024, an estimated $5.3M.
  • Cramer Rosenthal McGlynn first reported a position in Humana in Q1 2018 and held it in 18 quarters.
  • Cramer Rosenthal McGlynn's Humana position peaked at $85M in Q2 2018.
  • 1,029 funds tracked by Wall St. Rank held Humana as of Q1 2024.

Based on Cramer Rosenthal McGlynn's 13F filing for Q1 2024, filed 14 May 2024.